Author
|
Submitted to: Current Topics in Microbiology and Immunology
Publication Type: Book / Chapter Publication Acceptance Date: 12/6/2004 Publication Date: 6/1/2009 Citation: Hammond, R., Nemchinov, L.G. 2009. Plant Production Of Veterinary Vaccines and Therapeutics. Current Topics in Microbiology and Immunology. 332:79-102. Interpretive Summary: Existing animal disease control strategies are often ineffective or their implementation is problematic. Contaminated reagents and time consuming administration of vaccines contribute to the problem. In recent years, the use of plants for the production of bioengineered vaccines, antibodies, and enzymes has shown promise. The advantages of plants as production systems include safety, affordability, rapid turn around time, rapid scale up, ease of storage and purification, among others. The expressed protein can also be fed directly as plant material to animals. The intent of this chapter is to present the first concise overview of the current state of knowledge on the development of efficacious veterinary vaccines and therapeutic proteins in plants using transgenic and virus-based vector technologies. The chapter will be a valuable reference for an international audience of researchers, clinicians, and representatives of industry, academia, and government organizations with an interest in plant-based systems for production of recombinant medicines, vaccinology, immunology, and veterinary health. Technical Abstract: Plant-derived biologicals for use in animal health are becoming an increasingly important target for research into alternative, improved methods for disease control. Although there are no commercial products in the market yet, the development and testing of oral, plant-based vaccines is now beyond the 'proof of principal' stage. Vaccines, such as those developed for porcine transmissible gastroenteritis virus, have the potential to stimulate both mucosal, systemic, as well as lactogenic, immunity as has already been seen in target animal trials. Plants are a promising production system, but they must compete with existing vaccines and protein production platforms. In addition, regulatory hurdles will need to be overcome, and industry and public acceptance of the technology are important in establishing successful products. |
